Physicians, patients and analysts had new questions following the release of first-year results from a two-year National Institutes of Health study that found Avastin (bevacizumab), an FDA-approved cancer drug commonly used off-label, as effective as FDA-approved Lucentis (ranibizumab) in treating age-related macular degeneration (AMD).